Summary
Johnson & Johnson's 2005 Form 10-K report highlights a robust, diversified healthcare business operating across three core segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. The company's global reach is extensive, with operations in 56 countries and a workforce of approximately 115,600 employees. A decentralized management structure allows for operational flexibility, while a strong emphasis on research and development underpins its innovation-driven strategy. The company's significant brand portfolio and its commitment to product development across various health sectors position it as a leader in the global healthcare market.
Key Highlights
- 1Johnson & Johnson operates through three primary segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics, demonstrating a diversified revenue base.
- 2The company has a significant global presence, with operations in 56 countries and a workforce of approximately 115,600 employees.
- 3Key pharmaceutical products include RISPERDAL®, PROCRIT®/EPREX®, and REMICADE®, which accounted for a substantial portion of revenue.
- 4The Consumer segment boasts well-known brands such as BAND-AID®, TYLENOL®, and NEUTROGENA®.
- 5The Medical Devices and Diagnostics segment covers a broad range of products, including orthopaedics, surgical instruments, and diagnostic tools.
- 6The company is actively engaged in research and development, with worldwide research costs totaling $6,312 million for fiscal year 2005.
- 7Patent expirations for DURAGESIC® and EPREX® are noted as potential risks, with RISPERDAL®'s patent set to expire in December 2007.